Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Loss of RESponse to Ustekinumab Treated by Dose Escalation

NCT04245215 is registered in ClinicalTrials.gov with Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW as lead sponsor.

NCT NCT04245215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04245215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Loss of RESponse to Ustekinumab Treated by Dose Escalation
Lead sponsor
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Phase
Phase 3
Overall status
Completed
Start date
March 11, 2020
Completion date
September 25, 2024
Enrollment
108 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease